CJC-1295 + Ipamorelin Stack (Dual-Vial GH Axis Kit)
Analytical Standards & Laboratory Handling
Verified laboratory protocols, reconstitution parameters, and handling guidelines.
Pharmacological Profile & Mechanism of Action
What it is: The gold-standard dual secretagogue research stack combining CJC-1295 No DAC (5mg tetrasubstituted GHRH 1-29) and Ipamorelin (5mg pentapeptide ghrelin mimetic) in two separate sterile analytical vials.
How it works: When administered together, CJC-1295 binds to the GHRH receptor on anterior pituitary somatotropes to amplify the amplitude of growth hormone synthesis, while Ipamorelin selectively activates the GH secretagogue receptor (GHSR-1a) to trigger immediate exocytic release. This simultaneous dual-receptor gating produces a multi-fold amplified physiological GH pulse without stimulating prolactin, cortisol, or ACTH.
CRITICAL LABORATORY RECONSTITUTION & ASSAY HANDLING: Reconstitute both vials separately with 2.0 mL BAC water each. Administer co-temporaneously 30 minutes before sleep on an empty stomach.
Compound & Molecular Specifications
Certificate of Analysis StandardsFrequently Stacked with CJC-1295 No DAC (Mod GRF 1-29)
Clinically verified combinations activating complementary physiological pathways without receptor competition.
Ipamorelin (GHRP Selective)
CJC-1295 (GHRH agonist) stimulates the synthesis and transcription of Growth Hormone in pituitary somatotropes, while Ipamorelin (selective GHSR agonist) suppresses somatostatin and triggers the vesicular release pulse. Together they produce an amplified physiological GH pulse up to 5x higher than either alone.
